
Treatment-resistant depression (TRD) poses significant public health challenges, yet a consensus definition for TRD remains elusive, hindering accurate prevalence estimates and effective interventions. The US FDA and European Medicines Agency define it as an inadequate response to two or more antidepressants despite appropriate trials and adherence. Roughly 30% of depressed individuals fit this definition, but many are pseudo-resistant due to trial inadequacies or non-adherence. Some treatments like ketamine, esketamine, and second-gen antipsychotics show promise, while therapies like repetitive TMS and electroconvulsive therapy offer options.
Like
Save
Share